Markets:

Overview

News

Currencies

International

Treasuries

iRadimed Corporation - Common Stock (NQ:IRMD)

97.95 -0.35 (-0.36%)

Streaming Delayed Price Updated: 11:44 AM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about iRadimed Corporation - Common Stock

< Previous 1 2 3 Next >

IRadimed (IRMD) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

IRadimed (IRMD) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Iradimed (IRMD) CEO Sold 5,000 Shares Worth $413,216 ↗

November 09, 2025

Iradimed (IRMD) CEO Sold 5,000 Shares Worth $413,216

Via The Motley Fool

Topics Regulatory Compliance

IRADIMED CORP (NASDAQ:IRMD) Reports Strong Q3 2025 Earnings, Beats Estimates and Raises Guidance ↗

November 03, 2025

Iradimed (IRMD) beat Q3 2025 earnings and revenue estimates, achieving record sales. The MRI device specialist also raised its full-year 2025 guidance, signaling strong momentum.

Via Chartmill

Topics Earnings

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

Preview: iRadimed's Earnings ↗

October 31, 2025

Via Benzinga

US Market's Undiscovered Gems: Three Promising Stocks Poised for Investor Attention

October 09, 2025

In a financial landscape often dominated by mega-cap technology giants and established blue-chip companies, astute investors are continuously on the hunt for "undiscovered gems"—smaller, often...

Via MarketMinute

Earnings Preview: iRadimed ↗

July 31, 2025

Via Benzinga

Iradimed (IRMD) Q2 Revenue Jumps 14% ↗

August 02, 2025

Via The Motley Fool

IRADIMED CORP (NASDAQ:IRMD) Reports Record Q2 2025 Earnings, Raises Full-Year Guidance Amid Strong Market Rally ↗

August 01, 2025

IRADIMED CORP (IRMD) reported record Q2 2025 earnings, beating estimates with $20.4M revenue and $0.49 EPS. Shares surged 6.27% pre-market as the company raised full-year guidance.

Via Chartmill

Earnings Scheduled For August 1, 2025 ↗

August 01, 2025

Via Benzinga

Earnings Scheduled For May 5, 2025 ↗

May 05, 2025

Via Benzinga

Earnings Scheduled For February 13, 2025 ↗

February 13, 2025

Via Benzinga

Should you consider IRADIMED CORP (NASDAQ:IRMD) for quality investing? ↗

February 11, 2025

A fundamental analysis of (NASDAQ:IRMD): Why IRADIMED CORP (NASDAQ:IRMD) qualifies as a quality stock.

Via Chartmill

IRADIMED CORP (NASDAQ:IRMD) – A Quality Stock Worth Considering ↗

June 24, 2025

IRADIMED CORP (NASDAQ:IRMD) is a financially strong, debt-free company with high profitability and growth potential, making it a compelling choice for quality investors.

Via Chartmill

IRadimed Corp (NASDAQ:IRMD) – A Quality Stock Worth Considering ↗

June 03, 2025

IRadimed Corp (NASDAQ:IRMD) is a debt-free, high-ROIC medical device company with strong profitability and cash flow, making it a candidate for quality investors.

Via Chartmill

Why IRADIMED CORP (NASDAQ:IRMD) should be investigated by quality investors. ↗

May 08, 2025

A fundamental analysis of (NASDAQ:IRMD): Should you consider IRADIMED CORP (NASDAQ:IRMD) for quality investing?

Via Chartmill

Intuitive Surgical Gets Rating Upgrade. No. 1 In Its Industry; Profits, Sales Climbing. ↗

April 09, 2025

Intuitive Surgical, No. 1 stock in its group, has a deep moat around its technology and has sold is robotic surgical systems for 30 years.

Via Investor's Business Daily

Topics Initial Public Offering

Reasonable Growth, Debt Levels, and a High ROIC Make IRADIMED CORP (NASDAQ:IRMD) Appealing to Quality Investors. ↗

January 21, 2025

Why the quality investor may take a look at IRADIMED CORP (NASDAQ:IRMD).

Via Chartmill

Exploring NASDAQ:IRMD's quality characteristics. ↗

December 31, 2024

Reasonable growth and debt and a high ROIC for IRADIMED CORP (NASDAQ:IRMD).

Via Chartmill

Earnings Scheduled For February 8, 2024 ↗

February 08, 2024

Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share on revenue of $864.54 million.

Via Benzinga

iRadimed's Earnings Outlook ↗

February 07, 2024

Via Benzinga

Wednesday Is Your Last Chance To Buy iRadimed Before The Dividend Payout ↗

December 18, 2023

Via Benzinga

Masimo Stock Gets Relative Strength Rating Upgrade ↗

October 01, 2024

The Relative Strength Rating for Masimo stock jumped into a higher percentile Tuesday, as it got a lift from 69 to 78.

Via Investor's Business Daily

IRMD Stock Earnings: iRadimed Beats EPS, Beats Revenue for Q1 2024 ↗

May 02, 2024

IRMD stock results show that iRadimed beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Bruker Stock Rising, Near Buy Point; Gets Rating Upgrade ↗

January 30, 2024

A Relative Strength Rating upgrade for Bruker stock shows improving technical performance. Will it continue?

Via Investor's Business Daily

iRadimed's Earnings: A Preview ↗

November 02, 2023

Via Benzinga

Caleres, Cloudflare And 2 Other Stocks Insiders Are Selling ↗

October 13, 2023

The Nasdaq 100 closed lower by more than 50 points on Thursday. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

Should you consider NASDAQ:IRMD for quality investing? ↗

August 22, 2023

Should you consider IRADIMED CORP (NASDAQ:IRMD) for quality investing?

Via Chartmill

iRadimed: Q1 Earnings Insights ↗

May 04, 2023

Via Benzinga

Earnings Scheduled For November 3, 2023 ↗

November 03, 2023

Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report quarterly loss at $0.86 per share on revenue of $32.83 million.

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.